Viking Therapeutics shares rise 2.42% premarket after positive top-line results from Phase 2 clinical trial of VK2735.

Viking Therapeutics, Inc. rose 2.42% in premarket trading. The company announced positive top-line results from its Phase 2 clinical trial of VK2735, an oral tablet formulation for the treatment of obesity. The study showed statistically significant reductions in body weight with once-daily VK2735 dosing compared to placebo, with up to 12.2% mean weight loss observed after 13 weeks of treatment. The drug was also shown to be safe and well-tolerated.